Skip to the main content.
Facebook Instagram Linkedin X YouTube Medium

megamenu-services

 

Turn Vision into Velocity with the Innovation CRO

Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.

All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.

Explore our Services

megamenu-solutions-expertise

 

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Solutions
Expertise

megamenu-company-2

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Explore our Company

Sofia Spjuth

Sofia Spjuth, Vice President of Clinical Affairs, Europe at Veranex, is a medical device engineer with 10+ years of experience in the medtech industry. She is a member of SIS/TC 340 and SIS/TC 331, Technical Committees defending Swedish interests in European and global medical device standardization. Sofia is a nominated Swedish expert in ISO/TC 194 WG 4 (clinical investigations of medical devices) and participated in the development of both ISO 14155:2020 and the forthcoming fourth edition.